Over the years, MUJHU has been directly involved in several ground breaking research initiatives and clinical trials that have informed policy both with in Uganda and the world over. Several Studies have been undertaken and completed successfully with resounding results and several more are currently ongoing. The goal remains the same, lead the way in HIV AIDS research and improve the lives of those infected and affected by HIV.
Along the way, over 10,000 women have been enrolled in perinatal HIV prevention trials at MUJHU including the landmark HIVNET 012 (single dose Nevirapine for mother and baby), HPTN 046 (extended infant NVP prophylaxis during breastfeeding) and IMPAACT PROMISE (triple antiretroviral therapy during pregnancy and breastfeeding). Results from these studies have directly informed WHO policy advances to the current policy recommending antiretroviral therapy for life for all HIV-infected pregnant and breastfeeding women.